ClinicalTrials.gg
CompletedNCT01831427Updated Feb 1, 2021Results posted

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

A Phase 1 interventional study of Andecaliximab and Placebo to match Andecaliximab in Ulcerative Colitis, sponsored by Gilead Sciences. Completed at 16 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
253rd of 499
74 · median 76
Started
2013
with 22 others
Phase 1
76 of 615
8 open now
Registered
168th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 253rd largest by enrollment of the 499 interventional ones that give a count, is one of 23 that started in 2013, is one of 76 in phase 1, and was the 168th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are as follows:

  • To assess the safety and tolerability of escalating single and multiple doses of GS-5745 (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as assessed by adverse events (AEs) and laboratory abnormalities
  • To assess the pharmacokinetics (PK) of GS-5745 (andecaliximab) in participants with moderate to severe UC.
Read the detailed description

The study will test the safety of the drug. Participants will be given different concentrations of the drug in Cohorts, starting from a lower dose to a higher dose.

Single-Dose Treatment:

A thorough assessment of safety and tolerability will be performed before escalating to the next higher dose. For example, the first 2 participants will be dosed in a staggered fashion 24 hours apart. Provided that there are no significant safety signals up to 24 hours post-dose for the first 2 participants, the remaining 4 participants will be dosed. A thorough assessment of safety and tolerability (through Day 14 post-dose) will be performed by the safety review committee before escalating to the next higher dose. Participants enrolled in a SAD cohort will be eligible to participate in a MAD or adaptive MAD cohort if eligibility criteria are met.

Multiple-Dose Treatment:

This design follows the same set-up as the Single-Dose Treatment. Dosing will not commence in the first MAD cohort until safety data from the second dose level SAD cohort has been reviewed through Day 15. Successive MAD cohorts will only be dosed after safety data from the previous, lower dose MAD cohort through Day 43 and the next higher dose SAD cohort through Day 15, have been reviewed by the safety review committee. An additional Adaptive MAD cohort will explore a subcutaneous dosing of andecaliximab 150 mg prefilled syringe once a week for 5 weeks.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or Female, 18 to 65 years of age
  • Negative pregnancy test at screening
  • Documented diagnosis of UC with a minimum disease extent of 15 centimeters (cm) from the anal verge
  • Mayo Score of at least 3 for the SAD cohort and Mayo Score of at least 6 for the MAD cohorts
  • Hepatic panel ( [AST], alanine aminotransferase [ALT], total , direct bilirubin, alkaline phosphatase, lactate dehydrogenase [LDH] ≤ 2 times the [ULN])
  • Serum creatinine ≤ 1.5 times the ULN
  • ≥ 10 grams per deciliter (g/dL) (both males and females)
  • (ANC) ≥ 1.5 x 10\^9/L (1,500 milli meters [mm]\^3)
  • ≥ 100 x 10\^9/L.

Key Exclusion Criteria:

  • Pregnant or lactating females
  • Exhibit severe UC/ active infection
  • Current use of oral at a dose equivalent to > 20 mg/day of prednisone
  • Any dose adjustment in oral corticosteroids or oral (6-MP, Azathioprine), or oral 5-aminosalicylate (5-ASA) compounds within 30 days of Baseline
  • Use of rectal formulations of 5-ASA compounds or corticosteroids within 2 weeks prior to randomization
  • Crohn's disease or indeterminate colitis
  • History of colectomy, partial colectomy, or dysplasia on
  • Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia
  • Treatment with Infliximab, Adalimumab, Natalizumab, Golimumab, Vedolizumab or Certolizumab within 8 weeks of randomization
  • Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the Investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)

    Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 1.0 mg/kg IV (SAD)

    Participants will receive andecaliximab 1.0 mg/kg on Day 1.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 2.5 mg/kg IV (SAD)

    Participants will receive andecaliximab 2.5 mg/kg on Day 1.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 5.0 mg/kg IV (SAD)

    Participants will receive andecaliximab 5.0 mg/kg on Day 1.

    Drug: Andecaliximab

  • Placebo comparator
    Placebo Pooled (SAD)

    Participants will receive placebo on Day 1.

    Drug: Placebo to match Andecaliximab

  • Experimental
    Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)

    Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 1.0 mg/kg IV (MAD)

    Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 2.5 mg/kg IV (MAD)

    Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 5.0 mg/kg IV (MAD)

    Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.

    Drug: Andecaliximab

  • Experimental
    Andecaliximab 150 mg SC (Adaptive MAD)

    Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.

    Drug: Andecaliximab

  • Placebo comparator
    Placebo Pooled (MAD)

    Participants will receive placebo on Days 1, 15, and 29.

    Drug: Placebo to match Andecaliximab

Interventions

  • Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

    Also known as: GS-5745

  • DrugPlacebo to match Andecaliximab

    Placebo to match andecaliximab administered by IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)

    TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

    Time frame: SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days

  2. Pharmacokinetic (PK) Parameter: Cmax (SAD)

    Cmax is defined as the maximum concentration of drug.

    Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43

  3. PK Parameter: Cmax (MAD)

    Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.

    Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36

  4. PK Parameter: Ctau (MAD)

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36

  5. PK Parameter: AUCinf (SAD)

    AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.

    Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43

  6. PK Parameter: AUCtau (MAD)

    AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.

    Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36

  7. PK Parameter: AUClast (SAD)

    AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.

    Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43

07

Results

Posted Feb 1, 2021

Participant flow

Participants were enrolled at study sites in the United States, and Europe. The first participant was screened on 28 March 2013. The last study visit occurred on 06 February 2015.

Participant flow — Overall Study
MilestoneAndecaliximab 0.3 mg/kg IV Single Ascending Dose (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV Multiple Ascending Doses (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Placebo Pooled (MAD)
Started555548888108
Completed54544767895
Not completed01010121013
Withdrew: Adverse event01000101002
Withdrew: Investigator's discretion00010000000
Withdrew: Withdrew consent00000020011

Outcome measures

PrimaryPercentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)

TEAEs are any AEs with an onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or any AEs leading to premature discontinuation of study drug.

Time frame:
SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)
percentage of participantsAndecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Andecaliximab IV Combined (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab IV Combined (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Andecaliximab IV+SC Combined (MAD)Placebo Pooled (MAD)
Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)0.020.020.060.025.025.025.075.062.562.556.350.054.862.5
PrimaryPharmacokinetic (PK) Parameter: Cmax (SAD)

Cmax is defined as the maximum concentration of drug.

Time frame:
Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
Reported as:
Mean · micrograms per milliliter (μg/mL)
Pharmacokinetic (PK) Parameter: Cmax (SAD)
micrograms per milliliter (μg/mL)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)
Pharmacokinetic (PK) Parameter: Cmax (SAD)9.4 ± 3.2832.7 ± 11.0877.8 ± 20.67210.0 ± 102.60
PrimaryPK Parameter: Cmax (MAD)

Cmax is defined as the maximum concentration of drug over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.

Time frame:
MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36
Reported as:
Mean · μg/mL
PK Parameter: Cmax (MAD)
μg/mLAndecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)
Day 19.0 ± 3.2333.7 ± 26.4357.1 ± 13.6695.3 ± 28.93NA ± NA
Day 2910.3 ± 5.0629.0 ± 10.8966.6 ± 15.02120.8 ± 21.1533.5 ± 42.47
PrimaryPK Parameter: Ctau (MAD)

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36
Reported as:
Mean · μg/mL
PK Parameter: Ctau (MAD)
μg/mLAndecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)
PK Parameter: Ctau (MAD)NA ± NANA ± NA0.8 ± 2.3627.2 ± 13.9916.0 ± 15.99
PrimaryPK Parameter: AUCinf (SAD)

AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.

Time frame:
Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
Reported as:
Mean · day*micrograms per milliliter(day*μg/mL)
PK Parameter: AUCinf (SAD)
day*micrograms per milliliter(day*μg/mL)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)
PK Parameter: AUCinf (SAD)9.4 ± 4.4466.6 ± 22.85240.8 ± 23.69817.3 ± 405.97
PrimaryPK Parameter: AUCtau (MAD)

AUCtau is defined as the area under the plasma concentration versus time curve over the dosing interval. Data for Day 1 was based on the data collected from Day 1 through Day 8. Data for Day 29 was based on the data collected from Day 29 through Day 36.

Time frame:
MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36
Reported as:
Mean · day*μg/mL
PK Parameter: AUCtau (MAD)
day*μg/mLAndecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)
PK Parameter: AUCtau (MAD)NA ± NA79.2 ± 53.98251.8 ± 88.15784.8 ± 262.5166.8 ± 164.53
PrimaryPK Parameter: AUClast (SAD)

AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last observable concentration.

Time frame:
Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
Reported as:
Mean · day*μg/mL
PK Parameter: AUClast (SAD)
day*μg/mLAndecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)
PK Parameter: AUClast (SAD)7.7 ± 2.5457.2 ± 26.96212.4 ± 38.79750.2 ± 412.42

Adverse events

Collected over SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andecaliximab 0.3 mg/kg IV (SAD)0/5 (0%)0/5 (0%)0/5 (0%)
Andecaliximab 1.0 mg/kg IV (SAD)0/5 (0%)1/5 (20%)0/5 (0%)
Andecaliximab 2.5 mg/kg IV (SAD)0/5 (0%)0/5 (0%)1/5 (20%)
Andecaliximab 5.0 mg/kg IV (SAD)0/5 (0%)0/5 (0%)3/5 (60%)
Andecaliximab IV Combined (SAD)0/20 (0%)1/20 (5%)4/20 (20%)
Placebo Pooled (SAD)0/4 (0%)0/4 (0%)1/4 (25%)
Andecaliximab 0.3 mg/kg IV (MAD)0/8 (0%)1/8 (12.5%)2/8 (25%)
Andecaliximab 1.0 mg/kg IV (MAD)0/8 (0%)1/8 (12.5%)6/8 (75%)
Andecaliximab 2.5 mg/kg IV (MAD)0/8 (0%)0/8 (0%)5/8 (62.5%)
Andecaliximab 5.0 mg/kg IV (MAD)0/8 (0%)0/8 (0%)5/8 (62.5%)
Andecaliximab IV Combined (MAD)0/32 (0%)2/32 (6.3%)18/32 (56.3%)
Andecaliximab 150 mg SC (Adaptive MAD)0/10 (0%)0/10 (0%)5/10 (50%)
Andecaliximab IV+SC Combined (MAD)0/42 (0%)2/42 (4.8%)23/42 (54.8%)
Placebo Pooled (MAD)0/8 (0%)1/8 (12.5%)5/8 (62.5%)
Most frequent serious events
Most frequent serious events
EventAndecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Andecaliximab IV Combined (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab IV Combined (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Andecaliximab IV+SC Combined (MAD)Placebo Pooled (MAD)
Colitis ulcerativeGastrointestinal disorders0/51/50/50/51/200/40/81/80/80/81/320/101/420/8
Cytomegalovirus infectionInfections and infestations0/51/50/50/51/200/40/80/80/80/80/320/100/420/8
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/51/50/50/51/200/40/80/80/80/80/320/100/420/8
AnaemiaBlood and lymphatic system disorders0/50/50/50/50/200/40/80/80/80/80/320/100/421/8
HypersensitivityImmune system disorders0/50/50/50/50/200/41/80/80/80/81/320/101/420/8
Most frequent other events
Showing 10 of 37
Most frequent other events
EventAndecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Andecaliximab IV Combined (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab IV Combined (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Andecaliximab IV+SC Combined (MAD)Placebo Pooled (MAD)
AnaemiaBlood and lymphatic system disorders0/50/50/51/51/200/40/83/82/80/85/320/105/423/8
Colitis ulcerativeGastrointestinal disorders0/50/50/50/50/200/40/80/80/80/80/320/100/422/8
FatigueGeneral disorders0/50/50/50/50/200/40/82/81/80/83/320/103/421/8
PyrexiaGeneral disorders0/50/50/50/50/200/40/80/80/80/80/320/100/422/8
NasopharyngitisInfections and infestations0/50/50/50/50/201/41/80/80/82/83/320/103/420/8
DizzinessNervous system disorders0/50/50/50/50/200/40/80/81/80/81/320/101/422/8
HeadacheNervous system disorders0/50/50/50/50/200/40/80/80/82/82/321/103/422/8
Parotid gland enlargementGastrointestinal disorders0/50/50/51/51/200/40/80/80/80/80/320/100/420/8
Salivary gland painGastrointestinal disorders0/50/50/51/51/200/40/80/80/80/80/320/100/420/8
ToothacheGastrointestinal disorders0/50/50/51/51/200/40/80/80/80/80/320/100/420/8

Baseline characteristics

The Safety Analysis Set included participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Placebo Pooled (MAD)Total
Mean42 ± 11.337 ± 11.345 ± 15.442 ± 12.941 ± 15.142 ± 13.939 ± 11.738 ± 13.750 ± 9.848 ± 8.844 ± 15.843 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Placebo Pooled (MAD)Total
Female4313353526338
Male1242135364536
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Placebo Pooled (MAD)Total
Hispanic or Latino000000000000
Not Hispanic or Latino55554888810874
Unknown or Not Reported000000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Andecaliximab 0.3 mg/kg IV (SAD)Andecaliximab 1.0 mg/kg IV (SAD)Andecaliximab 2.5 mg/kg IV (SAD)Andecaliximab 5.0 mg/kg IV (SAD)Placebo Pooled (SAD)Andecaliximab 0.3 mg/kg IV (MAD)Andecaliximab 1.0 mg/kg IV (MAD)Andecaliximab 2.5 mg/kg IV (MAD)Andecaliximab 5.0 mg/kg IV (MAD)Andecaliximab 150 mg SC (Adaptive MAD)Placebo Pooled (MAD)Total
Race — American Indian or Alaska Native000000000000
Race — Asian100001000002
Race — Black220010100208
Race — Native Hawaiian or Pacific Islander000000000000
Race — White2355377888864
Race — Other000000000000
Race — Not Permitted000000000000
08

Study locations

16 sites
  • Delta Research Partners LLC
    Monroe, Louisiana 71201, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889-5600, United States
  • Clinical Research Institute of Michigan
    Chesterfield Township, MI 48047, Michigan 48047, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 64012, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Community Research
    Cincinnati, Ohio 45255, United States
  • UZ Leuven
    Leuven, 3000, Belgium
  • GIRI
    Vancouver, British Columbia V6Z 2K5, Canada
  • LHSC University Campus
    London, Ontario N6A 5A5, Canada
  • Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet
    Debrecen, Hajdú-Bihar 4031, Hungary
  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar
    Budapest, Pest 1083, Hungary
  • Drug Research Centre
    Balatonfured, 8230, Hungary
  • Republican Clinical Hospital
    Chisinau, 2025, Moldova, Republic of
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • Academisch Ziekenhuis Maastricht
    Maastricht, 6229 HX, Netherlands
  • Institute of Pulmonology "Marius Nasta"
    Bucharest, 050159, Romania
09

References and documents

Publications

  • Bhandari BR, Fogel R, Onken J, Yen EH, Kanwar B, Subramanian GM, McHutchison GJ, et al. Safety and Efficacy of GS-5745 an Anti-Matrix Metalloproteinase 9 (MMP) Monoclonal Antibody in Patients with Moderately to Severely Active Ulcerative Colitis. Gastroenterology 2015;148 (4): S-1196.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2013 to primary completion in Jan 2015, 21 months.

Results were first posted in Feb 2021, 6 years after primary completion.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 21 months is above that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2013
First posted
Apr 15, 2013
StartActual
Mar 28, 2013
Primary completionActual
Jan 5, 2015
CompletionActual
Feb 6, 2015
Results first posted
Feb 1, 2021
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01831427
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 15, 2013
Start date
Mar 28, 2013
Primary completion
Jan 5, 2015
Completion
Feb 6, 2015
Results posted
Feb 1, 2021
Last update
Feb 1, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion